Literature DB >> 34751931

Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.

Pureum Kang1, Hye-Jung Park1, Chang-Keun Cho1, Yun Jeong Lee2, Jung-Woo Bae3, Choon-Gon Jang1, Seok-Yong Lee4.   

Abstract

Tamsulosin, a selective [Formula: see text]-adrenoceptor blocker, is commonly used for alleviation of lower urinary tract symptoms related to benign prostatic hyperplasia. Tamsulosin is predominantly metabolized by CYP3A4 and CYP2D6 enzymes, and several studies reported the effects of CYP2D6 genetic polymorphism on the pharmacokinetics of tamsulosin. This study aims to develop and validate the physiologically based pharmacokinetic (PBPK) model of tamsulosin in CYP2D6*wt/*wt, CYP2D6*wt/*10, and CYP2D6*10/*10 genotypes, using Simcyp® simulator. Physicochemical, and formulation properties and data for absorption, distribution, metabolism and excretion were collected from previous publications, predicted in the simulator, or optimized in different CYP2D6 genotypes. The tamsulosin PBPK model in CYP2D6*wt/*wt and CYP2D6*wt/*10 genotypes were developed based on the clinical pharmacokinetic study where a single oral dose of 0.2 mg tamsulosin was administered to 25 healthy Korean male volunteers with CYP2D6*wt/*wt and CYP2D6*wt/*10 genotypes. A previous pharmacokinetic study was used to develop the model in CYP2D6*10/*10 genotype. The developed model was validated using other clinical pharmacokinetic studies not used in development. The predicted exposures via the PBPK model in CYP2D6*wt/*10 and CYP2D6*10/*10 genotype was 1.23- and 1.76-fold higher than CYP2D6*wt/*wt genotype, respectively. The simulation profiles were visually similar to the observed profiles, and fold errors of all development and validation datasets were included within the criteria. Therefore, the tamsulosin PBPK model in different CYP2D6 genotypes with regards to CYP2D6*10 alleles was appropriately established. Our model can contribute to the implementation of personalized pharmacotherapy of patients, appropriately predicting the pharmacokinetics of tamsulosin reflecting their demographic and CYP2D6 genotype characteristics without unnecessary drug exposure.
© 2021. The Pharmaceutical Society of Korea.

Entities:  

Keywords:  CYP2D6; Genetic polymorphism; PBPK; Pharmacokinetics; Tamsulosin

Mesh:

Substances:

Year:  2021        PMID: 34751931     DOI: 10.1007/s12272-021-01357-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  56 in total

1.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.

Authors:  Leonid M Berezhkovskiy
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

2.  Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype.

Authors:  Chang-Ik Choi; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  J Clin Pharmacol       Date:  2012-01-12       Impact factor: 3.126

3.  Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.

Authors:  Ji-Yeong Byeon; Young-Hoon Kim; Han-Sung Na; Jong-Hwa Jang; Se-Hyung Kim; Yun-Jeong Lee; Jung-Woo Bae; In Su Kim; Choon-Gon Jang; Myeon-Woo Chung; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2015-08-09       Impact factor: 4.946

4.  Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.

Authors:  Bruce K Birmingham; Sarah R Bujac; Robert Elsby; Connie T Azumaya; Julie Zalikowski; Yusong Chen; Kenneth Kim; Helen J Ambrose
Journal:  Eur J Clin Pharmacol       Date:  2015-01-30       Impact factor: 2.953

5.  Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties.

Authors:  Christine M Bowman; Leslie Z Benet
Journal:  Pharm Res       Date:  2019-05-31       Impact factor: 4.200

6.  CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.

Authors:  Ji-Young Byeon; Young-Hoon Kim; Choong-Min Lee; Se-Hyung Kim; Won-Ki Chae; Eui-Hyun Jung; Chang-Ik Choi; Choon-Gon Jang; Seok-Yong Lee; Jung-Woo Bae; Yun Jeong Lee
Journal:  Arch Pharm Res       Date:  2018-09-06       Impact factor: 4.946

7.  Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine.

Authors:  Ji-Yeong Byeon; Choong-Min Lee; Yea-Jin Lee; Young-Hoon Kim; Se-Hyung Kim; Eui Hyun Jung; Won Ki Chae; Yun Jeong Lee; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2018-12-12       Impact factor: 4.946

8.  Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes.

Authors:  Ji-Yeong Byeon; Yun Jeong Lee; Young-Hoon Kim; Se-Hyung Kim; Choong-Min Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee; Chang-Ik Choi
Journal:  Arch Pharm Res       Date:  2018-05-04       Impact factor: 4.946

9.  Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.

Authors:  Jung-Woo Bae; Kyung-Yul Oh; So-Jung Yoon; Hyo-Bin Shin; Eui Hyun Jung; Chang-Keun Cho; Chang Woo Lim; Pureum Kang; Chang-Ik Choi; Choon-Gon Jang; Seok-Yong Lee; Yun Jeong Lee
Journal:  Arch Pharm Res       Date:  2020-11-27       Impact factor: 4.946

10.  Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers.

Authors:  Mu Seong Ban; Yu Kyong Kim; Byungwook Kim; Jina Jung; Yong-Il Kim; Jaeseong Oh; Kyung-Sang Yu
Journal:  Transl Clin Pharmacol       Date:  2020-11-24
View more
  3 in total

1.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

2.  Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.

Authors:  Choong-Min Lee; Pureum Kang; Chang-Keun Cho; Hye-Jung Park; Yun Jeong Lee; Jung-Woo Bae; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-06-28       Impact factor: 4.946

3.  Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.

Authors:  Sang-Sup Whang; Chang-Keun Cho; Eui Hyun Jung; Pureum Kang; Hye-Jung Park; Yun Jeong Lee; Chang-Ik Choi; Jung-Woo Bae; Hyung Sik Kim; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-08-26       Impact factor: 6.010

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.